CRISPR Therapeutics, a leading gene-editing biopharmaceutical company focused on developing transformative medicines using its proprietary gene-editing platform, officially became a publicly traded company in the autumn of 2016. The company priced its initial public offering and began trading its common shares on the Nasdaq Global Market under the ticker symbol CRSP on October 19, 2016. This milestone public offering marked a major moment for the field of genetic medicine, providing the enterprise with the financial resources necessary to advance its pioneering CRISPR-based therapies through preclinical evaluation and subsequent landmark clinical trials.